Literature DB >> 2841490

In vivo and in vitro models of demyelinating disease: efficiency of virus spread and formation of infectious centers among glial cells is genetically determined by the murine host.

G A Wilson1, S Dales.   

Abstract

Resistance or susceptibility of various mouse strains to central nervous system disease caused by different strains of coronavirus is well known. Data from the present study draw attention to an additional, genetically determined mechanism controlling CV infections. The resistance to A59 and JHM virus (JHMV) associated with SJL mice was maintained in explanted glial cultures which, by contrast, fully supported a productive infection by the serorelated mouse hepatitis virus type 3. A comparative analysis of the infectious process in glial cell explants from SJL and CD.1 mice helped to define the stage at which restriction is manifested. Cultures of oligodendrocytes and astrocytes from these strains of mice were challenged with JHMV or mouse hepatitis virus type 3, and cell-virus interactions were monitored, including adsorption, uptake of inoculum, transcription, and cell-to-cell dissemination. The sequence of early events from adsorption to genome activation occurred with about equal efficiency with both viruses and genetically different cells, indicating that SJL resistance is not due to any deficiency in specific receptors or penetration of the inoculum or general expression of viral functions. However, intercellular spread of the infection was restricted in SJL glial cells owing to an as yet undefined component. Since cells from (SJL x CD.1)F1 mice were fully susceptible to JHMV, resistance to virus spread must be due to a deficiency in some factor, perhaps a proteolytic activity necessary for dissemination.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841490      PMCID: PMC253460          DOI: 10.1128/JVI.62.9.3371-3377.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide.

Authors:  S G Lazarowitz; P W Choppin
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

2.  Activation of influenza A viruses by trypsin treatment.

Authors:  H D Klenk; R Rott; M Orlich; J Blödorn
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

3.  Protease activation mutants of sendai virus. Activation of biological properties by specific proteases.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1976-01       Impact factor: 3.616

4.  Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

5.  In vivo and in vitro models of demyelinating diseases. III. JHM virus infection of rats.

Authors:  O Sorensen; D Perry; S Dales
Journal:  Arch Neurol       Date:  1980-08

6.  In vivo and in vitro models of demyelinating diseases: tropism of the JHM strain of murine hepatitis virus for cells of glial origin.

Authors:  A Lucas; W Flintoff; R Anderson; D Percy; M Coulter; S Dales
Journal:  Cell       Date:  1977-10       Impact factor: 41.582

7.  Genetic study of mouse sensitivity to MHV3 infection: influence of the H-2 complex.

Authors:  E Lévy-Leblond; D Oth; J M Dupuy
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

8.  Enhancement of plaque formation and cell fusion of an enteropathogenic coronavirus by trypsin treatment.

Authors:  J Storz; R Rott; G Kaluza
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

9.  On the entry of Semliki forest virus into BHK-21 cells.

Authors:  A Helenius; J Kartenbeck; K Simons; E Fries
Journal:  J Cell Biol       Date:  1980-02       Impact factor: 10.539

10.  In vivo and in vitro models of demyelinating disease. XVII. The infectious process in athymic rats inoculated with JHM virus.

Authors:  O Sorensen; A Saravani; S Dales
Journal:  Microb Pathog       Date:  1987-02       Impact factor: 3.738

View more
  8 in total

1.  Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors.

Authors:  K Yokomori; M M Lai
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  The receptor for mouse hepatitis virus in the resistant mouse strain SJL is functional: implications for the requirement of a second factor for viral infection.

Authors:  K Yokomori; M M Lai
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature.

Authors:  Marissa LoPresti; David B Beck; Priya Duggal; Derek A T Cummings; Benjamin D Solomon
Journal:  medRxiv       Date:  2020-06-03

4.  Acute and late disease induced by murine coronavirus, strain JHM, in a series of recombinant inbred strains between BALB/cHeA and STS/A mice.

Authors:  S Kyuwa; K Yamaguchi; Y Toyoda; K Fujiwara; J Hilgers
Journal:  Microb Pathog       Date:  1992-02       Impact factor: 3.738

5.  Identification of a contiguous 6-residue determinant in the MHV receptor that controls the level of virion binding to cells.

Authors:  P V Rao; S Kumari; T M Gallagher
Journal:  Virology       Date:  1997-03-17       Impact factor: 3.616

Review 6.  The molecular biology of coronaviruses.

Authors:  M M Lai; D Cavanagh
Journal:  Adv Virus Res       Date:  1997       Impact factor: 9.937

7.  Cell receptor-independent infection by a neurotropic murine coronavirus.

Authors:  T M Gallagher; M J Buchmeier; S Perlman
Journal:  Virology       Date:  1992-11       Impact factor: 3.616

8.  SJL/J resistance to mouse hepatitis virus-JHM-induced neurologic disease can be partially overcome by viral variants of S and host immunosuppression.

Authors:  J M Pasick; G A Wilson; V L Morris; S Dales
Journal:  Microb Pathog       Date:  1992-07       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.